Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations.
Schürmann
Dirk
D
Elston
Rob
R
Xu
Fan
F
Kleinkauf
Niels
N
Wünsche
Thomas
T
Suttorp
Norbert
N
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D002219:Carbamates / Q000627:therapeutic use*; D024882:Drug Resistance, Viral / Q000235:genetics; D004359:Drug Therapy, Combination; D005663:Furans; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009154:Mutation; D010755:Organophosphates / Q000627:therapeutic use*; D011355:Prodrugs / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use*
D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D010755:Organophosphates; D011355:Prodrugs; D013449:Sulfonamides; C095108:amprenavir; C426859:fosamprenavir